Strategic medical plans, their objectives and the initiatives that deliver them. Every initiative must trace to an approved objective.
Active plans
Objectives on track / at risk / off track
| Plan | Product | Scope | Lifecycle stage | Period | Status | Version | Owner | Budget planned vs actual | Review date |
|---|---|---|---|---|---|---|---|---|---|
Vantrexa Global Medical Plan FY2026 MP-2026-VTX-G | Vantrexa | Global | Launch | FY2026 | Active | v3 | PRDr. Priya Raman | 71% $5.9M of $8.4M | 01 Oct 2026 |
Vantrexa Japan Country Plan FY2026 MP-2026-VTX-JP | Vantrexa | Japan | Launch | FY2026 | Active | v2 | KWDr. Kenji Watanabe | 58% $640k of $1.1M | 15 Nov 2026 |
Nephrada Global Pre-launch Medical Plan FY2026 MP-2026-NPH-G | Nephrada | Global | Pre-launch | FY2026 | Active | v2 | MLDr. Marcus Lindqvist | 57% $2.4M of $4.2M | 15 Oct 2026 |
Lumeva Global Medical Plan FY2026 MP-2026-LMV-G | Lumeva | Global | Mature post-launch | FY2026 | Periodic review | v2 | EMDr. Elena Moretti | 80% $2.9M of $3.6M | 30 Sept 2026 |
Aurelin Global Medical Plan FY2026 MP-2026-ARL-G | Aurelin | Global | Late clinical development | FY2026 | Cross-functional review | v2 | TFDr. Tomás Ferreira | 46% $880k of $1.9M | 01 Dec 2026 |
| Objective | Product | Owner | Status | Progress | Confidence | Initiatives | Plan |
|---|---|---|---|---|---|---|---|
Establish vantrelimab as the preferred chemotherapy-free first-line option in PD-L1 ≥ 50% NSCLC amo… SO-VTX-01 | Vantrexa | PRDr. Priya Raman | On track | 68% | High | 2 | Vantrexa Global Medical Plan FY2026 |
Close the post-progression sequencing evidence gap through a real-world cohort and expert consensus. SO-VTX-02 | Vantrexa | NPDr. Nikolai Petrov | At risk | 41% | Medium | 2 | Vantrexa Global Medical Plan FY2026 |
Ensure PD-L1 testing readiness so that ≥ 80% of eligible patients in launch markets have a result w… SO-VTX-03 | Vantrexa | SLDr. Sophie Laurent | On track | 74% | Medium | 1 | Vantrexa Global Medical Plan FY2026 |
Deliver a complete, approved scientific communication platform and medical-information response lib… SO-VTX-04 | Vantrexa | DCDavid Chen | On track | 88% | High | 1 | Vantrexa Global Medical Plan FY2026 |
Achieve JSMO scientific presence and Tier 1 KOL coverage in Japan ahead of PMDA approval. SO-VTX-JP-01 | Vantrexa | KWDr. Kenji Watanabe | At risk | 52% | Medium | 1 | Vantrexa Japan Country Plan FY2026 |
Build understanding of proteinuria reduction as a validated surrogate endpoint among nephrologists… SO-NPH-01 | Nephrada | MLDr. Marcus Lindqvist | On track | 61% | Medium | 1 | Nephrada Global Pre-launch Medical Plan FY2026 |
Generate long-term eGFR slope evidence to support full approval and HTA submissions. SO-NPH-02 | Nephrada | NPDr. Nikolai Petrov | Off track | 22% | Low | 1 | Nephrada Global Pre-launch Medical Plan FY2026 |
Establish patient-advocacy partnerships to inform patient-relevant outcome measures. SO-NPH-03 | Nephrada | SLDr. Sophie Laurent | On track | 50% | Medium | 1 | Nephrada Global Pre-launch Medical Plan FY2026 |
Publish real-world persistence and switching evidence across three markets. SO-LMV-01 | Lumeva | EMDr. Elena Moretti | On track | 80% | High | 1 | Lumeva Global Medical Plan FY2026 |
Support the chronic-migraine lifecycle extension with a scientific platform and pre-submission KOL… SO-LMV-02 | Lumeva | EMDr. Elena Moretti | On track | 57% | Medium | 1 | Lumeva Global Medical Plan FY2026 |
Reduce medical-information response time for dosing and interaction queries to a median of 2 busine… SO-LMV-03 | Lumeva | FAFatima Al-Sayed | At risk | 45% | Medium | 1 | Lumeva Global Medical Plan FY2026 |
Map and begin engaging the dermatology KOL landscape in US and EU ahead of Phase III readout. SO-ARL-01 | Aurelin | TFDr. Tomás Ferreira | Not started | 12% | Medium | 1 | Aurelin Global Medical Plan FY2026 |
| Initiative | Type | Product | Objective | Owner | Dates | Status | Priority | Progress | Budget vs spend |
|---|---|---|---|---|---|---|---|---|---|
| Field medical campaign | Vantrexa | SO-VTX-01 | JWJames Whitfield | 15 Jan 2026 – 15 Dec 2026 | In progress | Critical | 66% | $418k / $620k | |
| RWE project | Vantrexa | SO-VTX-02 | NPDr. Nikolai Petrov | 01 Mar 2026 – 30 Jun 2027 | At risk | High | 30% | $310k / $1.4M | |
| Publication project | Vantrexa | SO-VTX-02 | DCDavid Chen | 01 Apr 2026 – 31 Dec 2026 | In progress | High | 55% | $52k / $95k | |
| Medical education program | Vantrexa | SO-VTX-03 | SLDr. Sophie Laurent | 01 Feb 2026 – 30 Nov 2026 | In progress | High | 78% | $296k / $380k | |
| Launch-readiness workstream | Vantrexa | SO-VTX-04 | DCDavid Chen | 10 Jan 2026 – 30 Sept 2026 | In progress | Critical | 90% | $221k / $240k | |
ESMO 2026 congress plan INI-0106 | Congress activity | Vantrexa | SO-VTX-01 | DCDavid Chen | 01 May 2026 – 31 Oct 2026 | In progress | High | 60% | $198k / $510k |
| Field medical campaign | Vantrexa | SO-VTX-JP-01 | KWDr. Kenji Watanabe | 01 Mar 2026 – 20 Dec 2026 | At risk | High | 48% | $172k / $310k | |
| Medical education program | Nephrada | SO-NPH-01 | ABDr. Anna Becker | 15 Feb 2026 – 15 Dec 2026 | In progress | High | 62% | $164k / $290k | |
| RWE project | Nephrada | SO-NPH-02 | NPDr. Nikolai Petrov | 01 Apr 2026 – 31 Dec 2028 | Blocked | Critical | 18% | $85k / $2.1M | |
| Advisory board | Nephrada | SO-NPH-03 | SLDr. Sophie Laurent | 01 May 2026 – 30 Nov 2026 | In progress | Medium | 50% | $41k / $85k | |
| Publication project | Lumeva | SO-LMV-01 | DCDavid Chen | 15 Jan 2026 – 30 Nov 2026 | In progress | High | 82% | $58k / $70k | |
| Advisory board | Lumeva | SO-LMV-02 | EMDr. Elena Moretti | 01 Mar 2026 – 31 Dec 2026 | In progress | Medium | 58% | $121k / $160k | |
| Medical-information improvement | Lumeva | SO-LMV-03 | FAFatima Al-Sayed | 01 Apr 2026 – 31 Oct 2026 | At risk | Medium | 45% | $22k / $40k | |
| Medical strategy initiative | Aurelin | SO-ARL-01 | TFDr. Tomás Ferreira | 01 Sept 2026 – 28 Feb 2027 | Planned | Medium | 10% | $0 / $120k |